HIV-1 Protease Mutation Scoring Algorithm for Tipranavir Susceptibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the effectiveness of tipranavir treatment for HIV-1 infections are imperfect, leading to unnecessary side effects and costs due to the inability to accurately determine drug susceptibility based on genotypic correlates.
Innovation Solution
Development of algorithms that analyze paired phenotypic and genotypic data to predict the effectiveness of anti-viral therapies by detecting specific mutations in the HIV-1 protease, allowing for the calculation of a mutation score to determine susceptibility to tipranavir.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If genotypic testing is used to determine HIV drug susceptibility, then the facilities required are cheaper and less complex, but the manual interpretation is difficult due to complex interaction patterns of resistance mutations
Solution Approach 1:
The patent segments the complex interpretation task by dividing it into two distinct algorithms: a rapid algorithm for initial screening that provides quick results, and a refined algorithm for final determination that provides accurate results. This segmentation allows the system to handle the complexity of mutation interactions without requiring complex facilities, as each algorithm handles a specific aspect of the interpretation process.
Solution Approach 2:
The patent introduces an intermediary computational system that automatically processes genotypic data through structured algorithms. This intermediary (computer-based interpretation system) mediates between the raw genotypic data and the clinical decision, eliminating the need for manual interpretation while maintaining accuracy. The algorithm acts as a bridge that translates complex mutation patterns into actionable susceptibility determinations.
2Reliability
If algorithms are developed to accurately predict treatment effectiveness, then patient outcomes improve and unnecessary treatments are reduced, but the development and implementation of such algorithms requires sophisticated data analysis capabilities
Solution Approach 1:
The patent divides the prediction system into two algorithmic components with distinct functions: a rapid algorithm for initial assessment and a refined algorithm for final determination. This segmentation allows the system to achieve high reliability through the refined algorithm while managing complexity by using the simpler rapid algorithm for preliminary screening, thus not requiring the full complexity to be activated in all cases.
Solution Approach 2:
The patent implements a two-stage approach where the rapid algorithm provides a partial assessment that is sufficient for initial triage, and the refined algorithm provides the complete accurate assessment when needed. This partial action approach allows the system to achieve high reliability for critical decisions while avoiding the complexity of always deploying the full refined algorithm, thus optimizing the balance between reliability and complexity.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides methods and devices for predicting whether an HIV-I is likely to have a reduced susceptibility to an antiviral drug based on the HIV- I 's genotype. In one aspect, the invention provides methods comprising determining whether a mutation or combination of mutations associated with altered susceptibility to protease inhibitors are present, as disclosed herein, thereby assessing the effectiveness of tipranavir therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV-I 's altered susceptibility are provided.